# A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct02030600` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02030600](<https://clinicaltrials.gov/study/NCT02030600>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02030600

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 721 participants.

## Technical summary

Registry record NCT02030600. Randomized; double masking; primary purpose treatment. Start 2014-01-06 (actual); primary completion 2015-12-04 (actual). Results posted on 2017-01-30.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 721 participants (enrolled count; ClinicalTrials.gov record NCT02030600, source copy `cardio:ctgov-nct02030600-2019-05-10`, retrieved 2026-10-26)
- Started: 2014-01-06 (actual) (ClinicalTrials.gov record NCT02030600, source copy `cardio:ctgov-nct02030600-2019-05-10`, retrieved 2026-10-26)
- Primary completion: 2015-12-04 (actual) (ClinicalTrials.gov record NCT02030600, source copy `cardio:ctgov-nct02030600-2019-05-10`, retrieved 2026-10-26)
- Completion: 2015-12-04 (actual) (ClinicalTrials.gov record NCT02030600, source copy `cardio:ctgov-nct02030600-2019-05-10`, retrieved 2026-10-26)
- Results first posted: 2017-01-30 (ClinicalTrials.gov record NCT02030600, source copy `cardio:ctgov-nct02030600-2019-05-10`, retrieved 2026-10-26)
- Countries: United States; Puerto Rico (ClinicalTrials.gov record NCT02030600, source copy `cardio:ctgov-nct02030600-2019-05-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02030600-2019-05-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes
- Acronym: SWITCH 2
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): insulin degludec
- Intervention (Drug): insulin glargine
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial (`cardio:pubmed-28672317`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2 (`cardio:pubmed-30891886`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e3943673c67e13d458ba98ec71672ae33d3f16dc8374cd6a13b6f96cc31ccf87
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
